Amarin reported $51.48M in Operating Expenses for its fiscal quarter ending in December of 2025.





Operating Expenses Change Date
AbbVie USD 10.52B 258M Sep/2026
Alnylam Pharmaceuticals USD 1.11B 52.78M Sep/2026
Amarin USD 51.48M 113K Dec/2025
AstraZeneca USD 11.55B 674M Sep/2026
BioCryst Pharmaceuticals USD -397.38M 517.17M Sep/2026
DBV Technologies USD 64.8M 16.9M Sep/2026
GlaxoSmithKline GBP 6.03B 227M Sep/2026
Halozyme Therapeutics USD 198M 4.66M Sep/2026
Heron Therapeutics USD 40.55M 1.46M Dec/2025
Ionis Pharmaceuticals USD 373M 2.76M Sep/2026
Nektar Therapeutics USD 49.12M 8.22M Mar/2026
Neurocrine Biosciences USD 779.7M 40.6M Sep/2026
Novartis USD 9.88B 325M Sep/2026